These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 8603941)

  • 1. Analysis of meningococcal serogroup C-specific antibody levels in British Columbian children and adolescents.
    Mitchell LA; Ochnio JJ; Glover C; Lee AY; Ho MK; Bell A
    J Infect Dis; 1996 Apr; 173(4):1009-13. PubMed ID: 8603941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adolescent meningococcal serogroup A, W and Y immune responses following immunization with quadrivalent meningococcal A, C, W and Y conjugate vaccine: Optimal age for vaccination.
    van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Sanders EAM; Berbers GAM
    Vaccine; 2017 Aug; 35(36):4753-4760. PubMed ID: 28647167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meningococcal serogroup C immunogenicity, antibody persistence and memory B-cells induced by the monovalent meningococcal serogroup C versus quadrivalent meningococcal serogroup ACWY conjugate booster vaccine: A randomized controlled trial.
    van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Knol MJ; Stoof SP; Sanders EAM; Berbers GAM
    Vaccine; 2017 Aug; 35(36):4745-4752. PubMed ID: 28668575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Age-related immunogenicity of meningococcal polysaccharide vaccine in aboriginal children and adolescents living in a Northern Manitoba reserve community.
    Law BJ; Rosenberg T; MacDonald NE; Ashton FE; Huang JC; King WJ; Ferris WJ; Gray GJ
    Pediatr Infect Dis J; 1998 Oct; 17(10):860-4. PubMed ID: 9802625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Total and functional antibody response to a quadrivalent meningococcal polysaccharide vaccine among children.
    King WJ; MacDonald NE; Wells G; Huang J; Allen U; Chan F; Ferris W; Diaz-Mitoma F; Ashton F
    J Pediatr; 1996 Feb; 128(2):196-202. PubMed ID: 8636811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meningococcal serogroup B-specific responses after vaccination with bivalent rLP2086: 4 year follow-up of a randomised, single-blind, placebo-controlled, phase 2 trial.
    Marshall HS; Richmond PC; Beeslaar J; Jiang Q; Jansen KU; Garcés-Sánchez M; Martinón-Torres F; Szenborn L; Wysocki J; Eiden J; Harris SL; Jones TR; Lee SS; Perez JL;
    Lancet Infect Dis; 2017 Jan; 17(1):58-67. PubMed ID: 27745812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protection against meningococcal serogroup ACYW disease in complement-deficient individuals vaccinated with the tetravalent meningococcal capsular polysaccharide vaccine.
    Fijen CA; Kuijper EJ; Drogari-Apiranthitou M; Van Leeuwen Y; Daha MR; Dankert J
    Clin Exp Immunol; 1998 Dec; 114(3):362-9. PubMed ID: 9844044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody persistence 3 years after immunization of adolescents with quadrivalent meningococcal conjugate vaccine.
    Vu DM; Welsch JA; Zuno-Mitchell P; Dela Cruz JV; Granoff DM
    J Infect Dis; 2006 Mar; 193(6):821-8. PubMed ID: 16479517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disease susceptibility to ST11 complex meningococci bearing serogroup C or W135 polysaccharide capsules, North America.
    Pollard AJ; Ochnio J; Ho M; Callaghan M; Bigham M; Dobsong S
    Emerg Infect Dis; 2004 Oct; 10(10):1812-5. PubMed ID: 15504268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody persistence after serogroup C meningococcal conjugate vaccine in children with sickle cell disease.
    Souza AR; Maruyama CM; Sáfadi MA; Lopes MH; Azevedo RS; Findlow H; Bai X; Borrow R; Weckx LY
    Vaccine; 2016 Aug; 34(36):4327-34. PubMed ID: 27395566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum factors and polymorphonuclear leukocytes in human host defence against Neisseria meningitidis. Studies of interactions with special reference to a chemiluminometric technique.
    Fredlund H
    Scand J Infect Dis Suppl; 1993; 87():1-72. PubMed ID: 8511525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term persistence of protective antibodies in Dutch adolescents following a meningococcal serogroup C tetanus booster vaccination.
    van Ravenhorst MB; Marinovic AB; van der Klis FR; van Rooijen DM; van Maurik M; Stoof SP; Sanders EA; Berbers GA
    Vaccine; 2016 Dec; 34(50):6309-6315. PubMed ID: 27817957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of a booster dose of meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine.
    Robertson CA; Greenberg DP; Hedrick J; Pichichero M; Decker MD; Saunders M
    Vaccine; 2016 Oct; 34(44):5273-5278. PubMed ID: 27642132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kinetics of Meningococcal Serogroup C-Specific Functional Antibody Levels Up to 15 Years after a Single Immunization with a Meningococcal Serogroup C Conjugate Vaccine during Adolescence.
    Stoof SP; van Ravenhorst MB; van Rooijen DM; de Voer RM; van der Klis FRM; Boland GJ; Sanders EAM; Berbers GAM; Teunis PF
    Clin Vaccine Immunol; 2017 Feb; 24(2):. PubMed ID: 27881489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serologic responses to ACYW135 polysaccharide meningococcal vaccine in Saudi children under 5 years of age.
    Al-Mazrou Y; Khalil M; Borrow R; Balmer P; Bramwell J; Lal G; Andrews N; Al-Jeffri M
    Infect Immun; 2005 May; 73(5):2932-9. PubMed ID: 15845499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meningococcal serogroup C-specific IgG antibody responses and serum bactericidal titres in children following vaccination with a meningococcal A/C polysaccharide vaccine.
    Borrow R; Richmond P; Kaczmarski EB; Iverson A; Martin SL; Findlow J; Acuna M; Longworth E; O'Connor R; Paul J; Miller E
    FEMS Immunol Med Microbiol; 2000 May; 28(1):79-85. PubMed ID: 10767611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of a serogroups A/C Neisseria meningitidis oligosaccharide-protein conjugate vaccine in young children. A randomized controlled trial.
    Lieberman JM; Chiu SS; Wong VK; Partidge S; Chang SJ; Chiu CY; Gheesling LL; Carlone GM; Ward JI
    JAMA; 1996 May; 275(19):1499-503. PubMed ID: 8622225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Analysis for protection rate and antibody levels of epidemic cerebrospinal meningitis among children aged between 3-23 months in Liuzhou, in 2012].
    Cui XL; Wu X; Li MQ
    Zhonghua Yu Fang Yi Xue Za Zhi; 2016 Dec; 50(12):1079-1083. PubMed ID: 28057112
    [No Abstract]   [Full Text] [Related]  

  • 19. Persistence of serum bactericidal antibody one year after a booster dose of either a glycoconjugate or a plain polysaccharide vaccine against serogroup C Neisseria meningitidis given to adolescents previously immunized with a glycoconjugate vaccine.
    de Whalley PC; Snape MD; Kelly DF; Banner C; Lewis S; Diggle L; John TM; Yu LM; Omar O; Borkowski A; Pollard AJ
    Pediatr Infect Dis J; 2011 Nov; 30(11):e203-8. PubMed ID: 21673612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MenACWY-TT vaccine for active immunization against invasive meningococcal disease.
    Papaevangelou V; Spyridis N
    Expert Rev Vaccines; 2012 May; 11(5):523-37. PubMed ID: 22827239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.